CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
sildenafildrug
Likely dose
sildenafil 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00659529
NCT00659529Phase 2Completed
CompareCT.gov

The Role of Phosphodiesterase Inhibitors in CF Lung Disease

National Jewish Health·interventional·Posted Apr 16, 2008·Updated May 14, 2026

In Brief

A Phase 2 clinical trial evaluating sildenafil for Cystic Fibrosis. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether sildenafil can decrease inflammation in CF lung disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
CollaboratorsCystic Fibrosis Foundation

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 16, 2008
Enrollment StartAug 1, 2008
Primary CompletionAug 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.2 years ago

Interventions

sildenafildrug

Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.